nyuuzyou/wikis huggingface dataset:
Trastuzumab-dttb (Ontruzant)

Note: this is a biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.
==General information==
Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*HER2+ breast cancer
*HER2+ esophageal cancer
*HER2+ gastric cancer
==Patient drug information==
To be completed
==History of changes in FDA indication==
*2019-01-18: Initial approval for the treatment of HER2 overexpressing breast cancer.
*2019-01-18: Initial approval for the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
==Also known as==
*Brand name: Ontruzant
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-HER2 antibodies
Category:Neutral
Category:Breast cancer medications
Category:Esophageal cancer medications
Category:Gastric cancer medications
Category:FDA approved in 2019
Category:Biosimilars
Category:WHO Essential Cancer Medicine
Trastuzumab-pkrb (Herzuma)

Note: this is a biosimilar.
==General information==
Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*HER2+ breast cancer
*HER2+ esophageal cancer
*HER2+ gastric cancer
==Patient drug information==
To be completed
==History of changes in FDA indication==
*2018-12-14: Initial approval for the treatment of HER2-overexpressing breast cancer.
==Supporting data==
#CT-P6 3.2: Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, Eniu A, Komov D, Morar-Bolba G, Li RK, Rusyn A, Lee SJ, Lee SY, Esteva FJ. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017 Jul;18(7):917-928. Epub 2017 Jun 4. Erratum in: Lancet Oncol. 2017 Aug;18(8):e433. Erratum in: Lancet Oncol. 2017 Sep;18(9):e510. link to original article EuroPMC NCT02162667
##Update: Esteva FJ, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu AE, Li RK, Rusyn AV, Tiangco B, Lee SJ, Lee SY, Yu SY, Stebbing J. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Cancer Chemother Pharmacol. 2019 Oct;84(4):839-847. Epub 2019 Aug 19. link to original article link to PMC article EuroPMC
##Update: Stebbing J, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Pikiel J, Eniu AE, Li RK, Tiangco B, Lee SJ, Kim S. Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. Breast Cancer Res Treat. 2021 Aug;188(3):631-640. Epub 2021 Jun 20. link to original article link to PMC article EuroPMC
==Also known as==
*Code name: CT-P6
*Brand name: Herzuma
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-HER2 antibodies
Category:Neutral
Category:Breast cancer medications
Category:Esophageal cancer medications
Category:Gastric cancer medications
Category:FDA approved in 2018
Category:Biosimilars
Category:WHO Essential Cancer Medicine
Trastuzumab-qyyp (Trazimera)

Note: this is a biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.
==General information==
Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*HER2+ breast cancer
*HER2+ esophageal cancer
*HER2+ gastric cancer
==Patient drug information==
To be completed
==History of changes in FDA indication==
*2019-03-11: Initial approval for the treatment of HER2 overexpressing breast cancer.
*2019-03-11: Initial approval for the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
==Also known as==
*Code name: PF-05280014
*Brand name: Trazimera
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-HER2 antibodies
Category:Neutral
Category:Breast cancer medications
Category:Esophageal cancer medications
Category:Gastric cancer medications
Category:FDA approved in 2019
Category:Biosimilars
Category:WHO Essential Cancer Medicine
Trastuzumab-strf (Hercessi)

Note: this is a biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.
==General information==
Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is established==
*HER2+ breast cancer
*HER2+ esophageal cancer
*HER2+ gastric cancer
==Patient drug information==
To be completed
==History of changes in FDA indication==
*2024-04-29: Initial approval for adjuvant treatment of HER2-overexpressing breast cancer.
*2024-04-29: Initial approval for the treatment of HER2-overexpressing metastatic breast cancer. (Based on HLX02-BC01)
*2024-04-29: Initial approval for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
==Also known as==
*Code name: HLX-02
*Brand name: Hercessi
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-HER2 antibodies
Category:Neutral
Category:Breast cancer medications
Category:Esophageal cancer medications
Category:Gastric cancer medications
Category:FDA approved in 2024
Category:Biosimilars
Category:WHO Essential Cancer Medicine
Trastuzumab and hyaluronidase (Herceptin Hylecta)

==Mechanism of action==
From the NCI Drug Dictionary: A ready-to-use combination of trastuzumab, a recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-oysk, a recombinant human hyaluronidase PH20 (rHuPH20), that may be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-oysk temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of trastuzumab into the bloodstream. 
==Diseases for which it is used==
*Breast cancer, HER2-positive
==History of changes in FDA indication==
*2019-02-28: Initial approval for the treatment of HER2-overexpressing breast cancer. (Based on HannaH)
==Also known as==
*Generic name: trastuzumab-oysk and hyaluronidase
*Brand name: Herceptin Hylecta
Category:Drugs
Category:Subcutaneous medications
Category:Protein expression-specific medications
Category:Anti-HER2 antibodies
Category:Neutral
Category:Breast cancer medications
Category:FDA approved in 2019
Travel award

Due to a generous grant from the Vanderbilt University School of Medicine, we are able to offer a small number of travel awards to qualified applicants. We intend to support one to two $500 travel awards for each of the following conferences:
*AMIA 2019 Annual Symposium in Washington, DC (Nov 16-20, 2019)
*61st ASH Annual Meeting & Exposition in Orlando, FL (Dec 7-10, 2019)
*ASCO Annual Meeting in Chicago, IL (May 29 – June 2, 2020)</big>
The intent of these travel awards is to support trainees (medical, nursing, pharmacy, etc.) to defray some of the costs of attending these professional society meetings. Strong preference will be given to applicants with work accepted to the conference of interest (e.g., a poster), although this is not a requirement. We are particularly interested in supporting work that utilizes new media, such as collaborative wikis, and measures the impact of such interventions on the hematology/oncology community. Given the lack of diversity in the field of hematology/oncology, preference will also be given to women, minority, and international applicants.
=Application instructions=
In order to apply, a trainee must provide an application package containing:
#A biosketch in NIH format
#A letter of support from their program director, confirming that they are in good standing and eligible to apply. 
#An application describing the applicant, general career plans, and how receiving a HemOnc.org travel award would be helpful in furthering these plans (limited to 2 pages maximum) 
Applications will be scored using the standard NIH approach, by:
#Significance
#Investigator
#Innovation
#Approach
#Environment
All applications will be judged independently by at least two reviewers, and all applicants will be provided with a short written critique. If the applicant is selected for an award, they will receive a $500 check from HemOnc.org LLC. No taxes will be withheld and it is the responsibility of the applicant to report this as gift income as required by their municipality. Anyone is allowed to apply, unless they appear on the United States Specially Designated Nationals And Blocked Persons List.
Completed applications should be submitted as a PDF document to travelaward@hemonc.org. Incomplete applications, applications in format other than PDF, and applications exceeding the page limit will be rejected without review.</big>
=Application deadlines=
So that we can give your application full consideration, the following deadlines will be strictly enforced (2 months prior to each conference):
*AMIA 2019: September 16, 2019
*ASH 2019: October 7, 2019
*ASCO 2020: March 29, 2020
We will notify you of our decision no later than one month prior to each conference (e.g., no later than November 7, 2019 for ASH). All decisions are final.
=Questions?=
Please email us with questions at either travelaward@hemonc.org or contact@hemonc.org.
Trebananib (AMG-386)

==General information==
Class/mechanism: Selective angiopoietin 1/2-neutralizing peptibody, interferes with interactions of angiopoietins and Tie2 receptors, inhibiting angiogenesis.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Ovarian cancer===
# TRINOVA-1: Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul;15(8):799-808. Epub 2014 Jun 17. link to original article EuroPMC NCT01204749
# TRINOVA-2: Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2017 Jan;70:111-121. Epub 2016 Dec 1. link to original article contains dosing details in abstract EuroPMC NCT01281254
# TRINOVA-3: Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):862-876. Epub 2019 May 7. link to original article contains dosing details in abstract EuroPMC NCT01493505
==Also known as==
*Code name: AMG-386
==References==
Category:Drugs
Category:Intravenous medications
Category:Peptibody medications
Category:Ovarian cancer medications (investigational)
Category:Halted drugs
Tremelimumab (Imjudo)

==General information==
Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.Tremelimumab (ticilimumab) information at Cancer.govAstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma (AstraZeneca)
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is established==
*Hepatocellular carcinoma
*Non-small cell lung cancer
==Diseases for which it is used==
*Colorectal cancer
*Urothelial carcinoma
==History of changes in FDA indication==
*2022-10-21: Approved in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). (Based on HIMALAYA)
*2022-11-10: Approved in combination with durvalumab and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (Based on POSEIDON)
==History of changes in EMA indication==
*2023-02-20: Initial authorisation as Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). (Based on HIMALAYA)
*2023-04-04: Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations. (Based on POSEIDON)
==History of changes in PMDA indication==
*2022-12-23: Initial approval
==Also known as==
*Code name: CP-675, CP-675206
*Generic name: ticilimumab
*Brand name: Imjudo
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-CTLA-4 antibodies
Category:Colorectal cancer medications
Category:Hepatocellular carcinoma medications
Category:Non-small cell lung cancer medications
Category:Urothelial carcinoma medications
Category:FDA approved in 2022
Category:EMA approved in 2023
Category:PMDA approved in 2022
Treosulfan (Ovastat)

==General information==
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.
Route: IV, PO
Extravasation: irritant
==Diseases for which it is used==
*Allogeneic HSCT
*Ovarian cancer
==History of changes in FDA indication==
*2025-01-21: Initial approval with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). (Based on MC-FludT.14/L)
==History of changes in EMA indication==
*2019-06-20: Initial authorization as Trecondi. Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases. 
*2023-03-06: Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
==Also known as==
*Brand names: Grafapex, Ovastat, Trecondi
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Alkylating agents
Category:Ovarian cancer medications
Category:EMA approved in 2019
Category:FDA approved in 2025
Trimetrexate (Neutrexin)

==General information==
Class/mechanism from DrugBank: In vitro studies have shown that trimetrexate is a competitive inhibitor of dihydrofolate reductase (DHFR) from bacterial, protozoan, and mammalian sources. DHFR catalyzes the reduction of intracellular dihydrofolate to the active coenzyme tetrahydrofolate. Inhibition of DHFR results in the depletion of this coenzyme, leading directly to interference with thymidylate biosynthesis, as well as inhibition of folate-dependent formyltransferases, and indirectly to inhibition of p.r.n. biosynthesis. The end result is disruption of DNA, RNA, and protein synthesis, with consequent cell death.
Route: IV
Extravasation: no information
==Diseases for which it is used==
No proven antineoplastic properties.
==Also known as==
*Generic names: trimetrexate glucuronate
*Brand name: Neutrexin
Category:Drugs
Category:Intravenous medications
Category:Antimetabolites
Category:Antifolates
Category:Antibacterials
Category:PCP prophylaxis
Category:FDA approved in 1993
Triptorelin (Trelstar LA)

==General information==
Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.Triptorelin (Trelstar LA) package insertTriptorelin (Trelstar LA) package insert (locally hosted backup)
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is used==
*Breast cancer
*Prostate cancer
==Patient drug information==
*Triptorelin (Trelstar LA) patient drug information (UpToDate)Triptorelin (Trelstar LA) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2000-06-15: Initial FDA approval in the palliative treatment of advanced prostate cancer. (Based on Heyns et al. 2003)
==History of changes in EMA indication==
*1986-03-05: EURD
==Also known as==
*Code names: AY-25650, CL-118532
*Generic name: triptorelin pamoate
*Brand names: Agotrig, Decapeptyl, Detryptoreline, Diphereline, Gonapeptyl, Ovugel, Pamorelin LA, Prostazar SR, Trelstar LA, Triptorin, Variopeptyl
==References==
Category:Drugs
Category:Intramuscular medications
Category:Antiandrogens
Category:GnRH agonists
Category:Breast cancer medications
Category:Prostate cancer medications
Category:FDA approved in 2000
Category:EMA approved in 1986
Category:WHO Essential Cancer Medicine
Tropisetron (Navoban)

==Mechanism of action==
From NCI: "An indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5-HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting."
==Also known as==
*Code name: ICS 205-930
*Brand names: Abatoarin, Hensetron, Navoban, Setrovel
 
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Emesis prevention
Category:Serotonin 5-HT3 antagonists
Category:EMA approved in 1992
Category:PMDA approved drugs
Category:KFDA approved drugs